南非低水平病毒血症患者HIV-1耐药检测的可行性与临床意义
该回顾性队列研究评估了南非约翰内斯堡公共实验室159例治疗经历成人低水平病毒血症(5-999拷贝/mL)样本的HIV基因型检测可行性及耐药流行情况。自建检测总成功率为78.6%,耐药突变 prevalence 达79.2%,提示在LLV阶段进行基因型检测可行,可能有助于更早识别需三线方案的患者。
要点
- 低水平病毒血症(5-999拷贝/mL)患者中自建HIV基因型检测成功率为78.6%。
- 获得序列的LLV患者中耐药突变患病率高达79.2%。
- 多数患者(68.6%)在基因型检测时使用含PI方案,主要PI突变占7.2%。
核心结论
- 在LLV患者中进行HIV基因型检测是可行的,可能有助于更早识别需三线方案的患者。
- 当前南非病毒学失败指南可能使患者在不必要的情况下继续使用失败方案过久。
研究设计与样本
- 观察性、回顾性队列研究,纳入2017年8月至2018年10月南非约翰内斯堡公共部门实验室常规送检HIVDR检测的LLV患者样本。
- 共分析159例HIV-1感染、有治疗经历的成人LLV(5-999拷贝/mL)血浆样本。
- 采用巢式RT-PCR和Sanger测序进行基因型检测,序列用Stanford HIVdb(版本8.7)解读耐药。
主要发现
- 自建检测总成功率为78.6%(125/159,95% CI 71.6-84.3)。
- LLV队列中耐药突变患病率为79.2%(99/125,95% CI 71.2-85.4)。
- 125条序列中,73.6%(92/125)有≥1个NRTI突变,70.4%(88/125)有≥1个NNRTI突变。
- 主要PI突变(包括M46I和V82A)在7.2%(9/125)的患者中检出。
- 多数患者(n=109,68.6%)在基因型检测时使用含PI方案。
临床怎么用
- 对LLV(5-999拷贝/mL)的治疗经历患者可考虑进行HIV基因型耐药检测。
- 检测结果可能支持更早识别需换用三线方案的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine the feasibility of HIV genotyping at low-level viraemia (LLV) using an in-house assay in a South African population and the prevalence, as well as the clinical relevance, of drug resistance (HIVDR) in this population. METHODS: We conducted an observational, retrospective, cohort study on patient samples with LLV referred for routine HIVDR testing at a public sector Johannesburg laboratory from August 2017 to October 2018. Genotyping was performed using a nested RT-PCR assay and Sanger sequencing. The genotyping success rate was evaluated for different viraemia categories. Sequences were loaded onto the Stanford HIVdb genotypic resistance tool (version 8.7) for drug resistance interpretation. RESULTS: Plasma samples from 159 HIV-1-infected, treatment-experienced adults with LLV (5-999 copies/mL) were analysed. The in-house assay performed well with an overall success rate of 78.6% (125/159, 95% CI 71.6-84.3). The prevalence of drug resistance mutations in the LLV cohort was 79.2% (99/125, 95% CI 71.2-85.4) with most patients (n = 109, 68.6%) on a PI-based regimen at the time of genotyping. Of 125 sequences obtained, 73.6% (92/125) had ≥1 NRTI mutation while 70.4% (88/125) had ≥1 NNRTI mutation. Major PI mutations, including M46I and V82A, were detected in 7.2% (9/125) of patients. CONCLUSIONS: Current South African virological failure guidelines may keep patients on failing regimens for longer than necessary. Our data suggest that genotyping at LLV is feasible and implementation could result in earlier identification and referral of patients requiring third-line regimens.
引用
- Bangalee A, Hans L, Steegen K, et al. Feasibility and clinical relevance of HIV-1 drug resistance testing in patients with low-level viraemia in South Africa. J Antimicrob Chemother. 2021. PMID: 34278422. doi:10.1093/jac/dkab220
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。